Christos Chatzakis, Nicolas Bourgon, Marianne Leruez-Ville, Yves Ville
{"title":"[围孕期和妊娠早期母体原发感染的丙环韦二级预防]。","authors":"Christos Chatzakis, Nicolas Bourgon, Marianne Leruez-Ville, Yves Ville","doi":"10.1016/j.gofs.2025.03.010","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Oral administration of valacyclovir at 8 g/day significantly reduces the rate of vertical transmission of CMV in women with a primary CMV infection acquired during the periconceptional period or the first trimester. The aim of this study is to expand the findings of previously published studies by including all recent cohorts on the subject.</p><p><strong>Methods: </strong>The MEDLINE, Scopus, Cochrane Central Register of Controlled Trials (Central), and \"clinical trial\" registry (www.</p><p><strong>Clinicaltrials: </strong>gov) were consulted. Randomized controlled trials and cohort studies administering oral valacyclovir at 8 g/day to pregnant women with a primary CMV infection acquired during the periconceptional period or the first trimester were included. Cochrane's Risk of Bias 2 and ROBINS-I tools were used to assess the risk of bias. The result of the CMV PCR in the amniotic fluid was the primary outcome. A two-step individual patient data meta-analysis was conducted, and a subgroup analysis was performed, evaluating periconceptional and first-trimester infections separately.</p><p><strong>Results: </strong>Four studies (1 RCT and 3 cohorts) were included in the analysis (n=860 women). A significant reduction in the rate of the CMV vertical transmission was observed in the Valacyclovir group (aOR=0.39, 95% CI 0.25-0.59). This reduction was significant for both the periconceptional period (aOR=0.30, 95% CI 0.13-0.68) and the first trimester (aOR=0.47, 95% CI 0.28-0.78). Valacyclovir also reduced the rate of neonatal infections, aOR=0.45 (95% CI 0.25-0.83), for both periods considered (aOR=0.42, 95% CI 0.20-0.90, and aOR=0.54, 95% CI 0.29-0.99).</p><p><strong>Conclusions: </strong>The current evidence suggests that oral valacyclovir (8 g/day) is associated with reduction of the rate of vertical transmission of CMV following maternal primary infection acquired during the periconceptional period or the first trimester of pregnancy.</p>","PeriodicalId":56056,"journal":{"name":"Gynecologie Obstetrique Fertilite & Senologie","volume":" ","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Secondary Prevention of Fetal Cytomegalovirus Infection Through Valacyclovir Administration in Maternal Primary Infections During the Periconceptional Period and First Trimester of Pregnancy].\",\"authors\":\"Christos Chatzakis, Nicolas Bourgon, Marianne Leruez-Ville, Yves Ville\",\"doi\":\"10.1016/j.gofs.2025.03.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Oral administration of valacyclovir at 8 g/day significantly reduces the rate of vertical transmission of CMV in women with a primary CMV infection acquired during the periconceptional period or the first trimester. The aim of this study is to expand the findings of previously published studies by including all recent cohorts on the subject.</p><p><strong>Methods: </strong>The MEDLINE, Scopus, Cochrane Central Register of Controlled Trials (Central), and \\\"clinical trial\\\" registry (www.</p><p><strong>Clinicaltrials: </strong>gov) were consulted. Randomized controlled trials and cohort studies administering oral valacyclovir at 8 g/day to pregnant women with a primary CMV infection acquired during the periconceptional period or the first trimester were included. Cochrane's Risk of Bias 2 and ROBINS-I tools were used to assess the risk of bias. The result of the CMV PCR in the amniotic fluid was the primary outcome. A two-step individual patient data meta-analysis was conducted, and a subgroup analysis was performed, evaluating periconceptional and first-trimester infections separately.</p><p><strong>Results: </strong>Four studies (1 RCT and 3 cohorts) were included in the analysis (n=860 women). A significant reduction in the rate of the CMV vertical transmission was observed in the Valacyclovir group (aOR=0.39, 95% CI 0.25-0.59). This reduction was significant for both the periconceptional period (aOR=0.30, 95% CI 0.13-0.68) and the first trimester (aOR=0.47, 95% CI 0.28-0.78). Valacyclovir also reduced the rate of neonatal infections, aOR=0.45 (95% CI 0.25-0.83), for both periods considered (aOR=0.42, 95% CI 0.20-0.90, and aOR=0.54, 95% CI 0.29-0.99).</p><p><strong>Conclusions: </strong>The current evidence suggests that oral valacyclovir (8 g/day) is associated with reduction of the rate of vertical transmission of CMV following maternal primary infection acquired during the periconceptional period or the first trimester of pregnancy.</p>\",\"PeriodicalId\":56056,\"journal\":{\"name\":\"Gynecologie Obstetrique Fertilite & Senologie\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2025-04-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gynecologie Obstetrique Fertilite & Senologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.gofs.2025.03.010\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologie Obstetrique Fertilite & Senologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.gofs.2025.03.010","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:口服8g /天的valacyclovir可显著降低在妊娠期或妊娠早期获得原发性巨细胞病毒感染的妇女巨细胞病毒的垂直传播率。本研究的目的是扩大以前发表的研究结果,包括所有最近的队列研究。方法:查阅MEDLINE、Scopus、Cochrane Central Register of Controlled Trials (Central)和“临床试验”登记处(www.Clinicaltrials: gov)。随机对照试验和队列研究纳入了在围孕期或妊娠早期获得原发性巨细胞病毒感染的孕妇口服8g /天的valacyclovir。使用Cochrane's Risk of Bias 2和ROBINS-I工具评估偏倚风险。羊水中巨细胞病毒聚合酶链反应的结果是主要结果。进行了两步个体患者数据荟萃分析,并进行了亚组分析,分别评估围孕期和妊娠早期感染。结果:4项研究(1项RCT和3个队列)纳入分析(n=860名女性)。缬昔洛韦组CMV垂直传播率显著降低(aOR=0.39, 95% CI 0.25-0.59)。这种减少在围孕期(aOR=0.30, 95% CI 0.13-0.68)和妊娠早期(aOR=0.47, 95% CI 0.28-0.78)都是显著的。在考虑的两个时期,伐昔洛韦也降低了新生儿感染率,aOR=0.45 (95% CI 0.25-0.83) (aOR=0.42, 95% CI 0.20-0.90, aOR=0.54, 95% CI 0.29-0.99)。结论:目前的证据表明,口服伐昔洛韦(8g /天)与降低围孕期或妊娠早期获得的母体原发性感染后巨细胞病毒的垂直传播率有关。
[Secondary Prevention of Fetal Cytomegalovirus Infection Through Valacyclovir Administration in Maternal Primary Infections During the Periconceptional Period and First Trimester of Pregnancy].
Objectives: Oral administration of valacyclovir at 8 g/day significantly reduces the rate of vertical transmission of CMV in women with a primary CMV infection acquired during the periconceptional period or the first trimester. The aim of this study is to expand the findings of previously published studies by including all recent cohorts on the subject.
Methods: The MEDLINE, Scopus, Cochrane Central Register of Controlled Trials (Central), and "clinical trial" registry (www.
Clinicaltrials: gov) were consulted. Randomized controlled trials and cohort studies administering oral valacyclovir at 8 g/day to pregnant women with a primary CMV infection acquired during the periconceptional period or the first trimester were included. Cochrane's Risk of Bias 2 and ROBINS-I tools were used to assess the risk of bias. The result of the CMV PCR in the amniotic fluid was the primary outcome. A two-step individual patient data meta-analysis was conducted, and a subgroup analysis was performed, evaluating periconceptional and first-trimester infections separately.
Results: Four studies (1 RCT and 3 cohorts) were included in the analysis (n=860 women). A significant reduction in the rate of the CMV vertical transmission was observed in the Valacyclovir group (aOR=0.39, 95% CI 0.25-0.59). This reduction was significant for both the periconceptional period (aOR=0.30, 95% CI 0.13-0.68) and the first trimester (aOR=0.47, 95% CI 0.28-0.78). Valacyclovir also reduced the rate of neonatal infections, aOR=0.45 (95% CI 0.25-0.83), for both periods considered (aOR=0.42, 95% CI 0.20-0.90, and aOR=0.54, 95% CI 0.29-0.99).
Conclusions: The current evidence suggests that oral valacyclovir (8 g/day) is associated with reduction of the rate of vertical transmission of CMV following maternal primary infection acquired during the periconceptional period or the first trimester of pregnancy.
期刊介绍:
Gynécologie Obstétrique Fertilité & Sénologie est un mensuel scientifique d''information et de formation destiné aux gynécologues, aux obstétriciens, aux sénologues et aux biologistes de la reproduction. La revue, dans ses éditoriaux, articles originaux, mises au point, lettres à la rédaction et autres rubriques, donne une information actualisée ayant trait à l''obstétrique et à la gynécologie et aux différentes spécialités développées à partir de ces deux pôles : médecine de la reproduction, médecine maternelle et fœtale, périnatalité, endocrinologie, chirurgie gynécologique, cancérologie pelvienne, sénologie, sexualité, psychosomatique…